Literature DB >> 17035541

Alpha-synuclein expression modulates microglial activation phenotype.

Susan A Austin1, Angela M Floden, Eric J Murphy, Colin K Combs.   

Abstract

Recent Parkinson's disease research has focused on understanding the function of the cytosolic protein, alpha-synuclein, and its contribution to disease mechanisms. Within neurons, alpha-synuclein is hypothesized to have a role in regulating synaptic plasticity, vesicle release, and trafficking. In contrast, glial-expressed alpha-synuclein remains poorly described. Here, we examine the consequence of a loss of alpha-synuclein expression on microglial activation. Using a postnatal brain-derived culture system, we defined the phenotype of microglia from wild-type and knock-out alpha-synuclein mice (Scna-/-). Scna-/- microglia displayed a basally increased reactive phenotype compared with the wild-type cells and an exacerbated reactive phenotype after stimulation. They also exhibited dramatic morphologic differences compared with wild-type, presenting as large, ramified cells filled with vacuole-like structures. This corresponded with increased protein levels of activation markers, CD68 and beta1 integrin, in the Scna-/- cells. More importantly, Scna-/- microglia, after stimulation, secreted elevated levels of proinflammatory cytokines, TNFalpha (tumor necrosis factor alpha) and IL-6 (interleukin-6), compared with wild type. However, despite the reactive phenotype, Scna-/- cells had impaired phagocytic ability. We demonstrate for the first time that alpha-synuclein plays a critical role in modulating microglial activation state. We suggest that altered microglial alpha-synuclein expression will affect their phenotype as has already been demonstrated in neurons. This has direct ramifications for the contribution of microglia to the pathophysiology of disease, particularly in familial cases linked to altered alpha-synuclein expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035541      PMCID: PMC6674709          DOI: 10.1523/JNEUROSCI.1799-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  45 in total

1.  Astrocytes modulate macrophage phagocytosis of myelin in vitro.

Authors:  M E Smith; M T Hoerner
Journal:  J Neuroimmunol       Date:  2000-01-24       Impact factor: 3.478

Review 2.  The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

Authors:  M G Spillantini; M Goedert
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 3.  Inflammation in Parkinson's disease.

Authors:  P L McGeer; K Yasojima; E G McGeer
Journal:  Adv Neurol       Date:  2001

4.  alpha-synuclein is developmentally expressed in cultured rat brain oligodendrocytes.

Authors:  C Richter-Landsberg; M Gorath; J Q Trojanowski; V M Lee
Journal:  J Neurosci Res       Date:  2000-10-01       Impact factor: 4.164

5.  Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia.

Authors:  W G Kim; R P Mohney; B Wilson; G H Jeohn; B Liu; J S Hong
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

6.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

7.  alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells.

Authors:  Bong-Hyun Ahn; Hyangshuk Rhim; Shi Yeon Kim; Young-Mo Sung; Mun-Yong Lee; Ju-Youn Choi; Benjamin Wolozin; Jong-Soo Chang; Young Han Lee; Taeg Kyu Kwon; Kwang Chul Chung; Shin-Hee Yoon; Sang June Hahn; Myung-Suk Kim; Yang-Hyeok Jo; Do Sik Min
Journal:  J Biol Chem       Date:  2002-01-30       Impact factor: 5.157

8.  Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein.

Authors:  Nelson B Cole; Diane D Murphy; Theresa Grider; Susan Rueter; Dawn Brasaemle; Robert L Nussbaum
Journal:  J Biol Chem       Date:  2001-12-14       Impact factor: 5.157

9.  Subcellular localization of alpha-synuclein in primary neuronal cultures: effect of missense mutations.

Authors:  P J McLean; S Ribich; B T Hyman
Journal:  J Neural Transm Suppl       Date:  2000

10.  Expression of beta-synuclein in normal human astrocytes.

Authors:  K Tanji; F Mori; S Nakajo; T Imaizumi; H Yoshida; T Hirabayashi; M Yoshimoto; K Satoh; H Takahashi; K Wakabayashi
Journal:  Neuroreport       Date:  2001-09-17       Impact factor: 1.837

View more
  66 in total

1.  The impact of glial activation in the aging brain.

Authors:  Aileen M Lynch; Kevin J Murphy; Brian F Deighan; Julie-Ann O'Reilly; Yuri K Gun'ko; Thelma R Cowley; Rodrigo E Gonzalez-Reyes; Marina A Lynch
Journal:  Aging Dis       Date:  2010-09-04       Impact factor: 6.745

Review 2.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

3.  Suppressed microglial E prostanoid receptor 1 signaling selectively reduces tumor necrosis factor alpha and interleukin 6 secretion from toll-like receptor 3 activation.

Authors:  Xianwu Li; Eiron Cudaback; C Dirk Keene; Richard M Breyer; Thomas J Montine
Journal:  Glia       Date:  2011-01-06       Impact factor: 7.452

Review 4.  Immune system responses in Parkinson's disease: Early and dynamic.

Authors:  Malú G Tansey; Marina Romero-Ramos
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

5.  Ultrastructural changes in peripheral blood leukocytes in α-synuclein knockout mice.

Authors:  Hammad Tashkandi; Afshin Shameli; Clifford V Harding; Robert W Maitta
Journal:  Blood Cells Mol Dis       Date:  2018-09-01       Impact factor: 3.039

Review 6.  Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration.

Authors:  Juan A Orellana; Pablo J Sáez; Kenji F Shoji; Kurt A Schalper; Nicolás Palacios-Prado; Victoria Velarde; Christian Giaume; Michael V L Bennett; Juan C Sáez
Journal:  Antioxid Redox Signal       Date:  2009-02       Impact factor: 8.401

7.  Effects of mitochondrial dysfunction on the immunological properties of microglia.

Authors:  Annette I Ferger; Loretta Campanelli; Valentina Reimer; Katharina N Muth; Irma Merdian; Albert C Ludolph; Anke Witting
Journal:  J Neuroinflammation       Date:  2010-08-11       Impact factor: 8.322

8.  Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.

Authors:  Cintia Roodveldt; Adahir Labrador-Garrido; Elena Gonzalez-Rey; Rafael Fernandez-Montesinos; Marta Caro; Christian C Lachaud; Christopher A Waudby; Mario Delgado; Christopher M Dobson; David Pozo
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

9.  Effects of chronic low dose rotenone treatment on human microglial cells.

Authors:  Shamim B Shaikh; Louise Fb Nicholson
Journal:  Mol Neurodegener       Date:  2009-12-31       Impact factor: 14.195

10.  Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.

Authors:  Vanesa Sanchez-Guajardo; Fabia Febbraro; Deniz Kirik; Marina Romero-Ramos
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.